FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reissued a market perform rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Trading Down 1.7 %

Shares of FibroGen stock opened at $0.40 on Friday. The firm has a fifty day simple moving average of $0.51 and a 200-day simple moving average of $1.04. The stock has a market capitalization of $39.73 million, a price-to-earnings ratio of -0.16 and a beta of 0.69. FibroGen has a 1-year low of $0.33 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same period in the prior year, the firm earned ($0.65) earnings per share. As a group, research analysts predict that FibroGen will post -0.91 earnings per share for the current year.

Institutional Trading of FibroGen

A number of large investors have recently bought and sold shares of FGEN. Point72 DIFC Ltd boosted its stake in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in FibroGen by 3,906.9% in the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in FibroGen during the second quarter worth about $130,000. Doheny Asset Management CA acquired a new stake in shares of FibroGen during the second quarter worth approximately $48,000. Finally, AQR Capital Management LLC increased its holdings in shares of FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares in the last quarter. 72.71% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.